Loomba R et al., SYNERGY-NASH, NEJM 2024 (NEJMoa2401943, PMID 38856224) : tirzepatide and MASH, resolution in 62% at the 15 mg level
Negative ion ultraviolet matrix-assisted laser desorption ionization mass spectrometry and post source decay of glycosyl esters of nucleoside pyrophosphates
This is one of the most interesting potential applications, though formal head-to-head data in this population is limited
This is one of the most common questions we hear from people starting weight loss medication
I was new to having fillers done and Lauren made sure I was comfortable and all of my questions were answered
To qualify, you must have a documented diagnosis of type 2 diabetes and have previously tried other standard, first-line glucose-lowering medications without achieving your target A1C goals